CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies (Q38807514)

6 September 2017

title

CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies (English)

1 reference

6 September 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27075017 AND SRC:MED&resulttype=core&format=json

3 June 2020

Safar Farajnia

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27075017 AND SRC:MED&resulttype=core&format=json

3 June 2020

author name string

Vahideh Ahmadzadeh

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27075017 AND SRC:MED&resulttype=core&format=json

3 June 2020

publication date

13 April 2016

1 reference

Investigational New Drugs

6 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27075017 AND SRC:MED&resulttype=core&format=json

3 June 2020

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27075017 AND SRC:MED&resulttype=core&format=json

3 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27075017 AND SRC:MED&resulttype=core&format=json

3 June 2020

page(s)

497-512

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27075017 AND SRC:MED&resulttype=core&format=json

CD20 deficiency in humans results in impaired T cell-independent antibody responses

3 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

CD20: a regulator of cell-cycle progression of B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Development trends for generation of single-chain antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

The biology of CD20 and its potential as a target for mAb therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

The epitope recognized by rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Proteomic analysis of S-acylated proteins in human B cells reveals palmitoylation of the immune regulators CD20 and CD23.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

CD20-mediated apoptosis: signalling through lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Store-operated cation entry mediated by CD20 in membrane rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Enhancement of Rituximab-induced cell death by the physical association of CD20 with CD40 molecules on the cell surface.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Therapeutic antibodies and antibody fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Understanding and circumventing resistance to anticancer monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Isolated plasmacytoma involving the brain parenchyma and cerebral spinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20 indolent NHL: correlation between clinical responses and AUC pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Novel humanized anti-CD20 antibody BM-ca binds to a unique epitope and exerts stronger cellular activity than others

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Eradication of non-Hodgkin lymphoma through the induction of tumor-specific T-cell immunity by CD20-Flex BiFP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig™) molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

A bispecific antibody directly induces lymphoma cell death by simultaneously targeting CD20 and HLA-DR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

⁹⁹mTc carbonyl DTPA-rituximab: preparation and preliminary bioevaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Production of an active anti-CD20-hIL-2 immunocytokine in Nicotiana benthamiana.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

High levels of reactive oxygen species in gold nanoparticle-targeted cancer cells following femtosecond pulse irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Nanoparticles engineered with rituximab and loaded with Nutlin-3 show promising therapeutic activity in B-leukemic xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Substituting Doxorubicin with nonpegylated liposomal Doxorubicin for the treatment of early breast cancer: results of a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Anti-CD20 multivalent HPMA copolymer-Fab' conjugates for the direct induction of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20 malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Targeting CD20 Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Stem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells Target Cancer Cells In Situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Human umbilical cord mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion protein delivery: a double-target therapy against non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20( ) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

90Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Rituximab and CHOP Chemotherapy Plus GM-CSF for Previously Untreated Diffuse Large B-Cell Lymphoma in the Elderly: A Wisconsin Oncology Network Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination with in-situ dendritic cell vaccination in advanced lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

BCR-bound antigen is targeted to exosomes in human follicular lymphoma B-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Sti1 is a non-competitive inhibitor of the Hsp90 ATPase. Binding prevents the N-terminal dimerization reaction during the atpase cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Requirement of apoptotic protease-activating factor-1 for bortezomib-induced apoptosis but not for Fas-mediated apoptosis in human leukemic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: effects of rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Combination of rituximab and mammalian target of rapamycin inhibitor everolimus (RAD001) in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Combined administration of rituximab and on 013105 induces apoptosis in mantle cell lymphoma cells and reduces tumor burden in a mouse model of mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20 tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Pancytopenia following vivax malaria in a CLL patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Prenyltransferases regulate CD20 protein levels and influence anti-CD20 monoclonal antibody-mediated activation of complement-dependent cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-016-0349-4

Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development

21 January 2018

1 reference

12 December 2020

Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.

1 reference

12 December 2020

A Bispecific Antibody-IFNα2b Immunocytokine Targeting CD20 and HLA-DR Is Highly Toxic to Human Lymphoma and Multiple Myeloma Cells

1 reference

12 December 2020

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

12 December 2020

CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101

1 reference

12 December 2020

Expression of B-cell surface antigens in subpopulations of exosomes released from B-cell lymphoma cells

1 reference

12 December 2020

Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody

1 reference

12 December 2020

CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma.

1 reference

12 December 2020

Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment

1 reference

12 December 2020

Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains

1 reference

12 December 2020

Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma

1 reference

12 December 2020

Phosphorylation of the B1 (CD20) molecule by normal and malignant human B lymphocytes

1 reference

12 December 2020

Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease

1 reference

12 December 2020

Mechanisms of action of CD20 antibodies

1 reference

12 December 2020

Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas

1 reference

12 December 2020

Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo

1 reference

12 December 2020

CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts.

1 reference

12 December 2020

Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects

1 reference

12 December 2020

Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma

1 reference

12 December 2020

Proteolytic pathways involved in modulation of CD20 levels

1 reference

12 December 2020